The Professional Association of Banks and Financial Institutions (الجمعية المهنية للبنوك والمؤسسات المالية) has issued a directive to bank executives concerning import files for management and equipment programs slated for the first half of 2026. This correspondence clarifies the deadlines for these programs, which are key for businesses in الجزائر. The association confirmed that the validity of estimated import programs for management for H1 2026 officially concluded on June 30, 2026. This communication aims to streamline the processing of import requests and ensure adherence to established timelines for the upcoming period, providing clear guidance to financial institutions across the country.
Key Exceptions Detailed
The stated deadline does not apply to tariff items that received bank settlement prior to June 30, 2026. For these specific items, bank settlement procedures are permitted to continue, utilizing the remaining quantities available on the Ministry of Foreign Trade and Export Promotion platform. This allowance ensures that import processes for certain goods can proceed despite the general deadline, preventing unnecessary disruptions for transactions already in progress. The directive explicitly states that this deadline does not apply to tariff items that had undergone bank settlement before June 30, 2026, offering a critical carve-out for ongoing operations.
The Professional Association of Banks and Financial Institutions further clarified that this particular exception applies exclusively to products that are subject to authorizations granted by the Ministry of Pharmaceutical Industry. This distinction notes a targeted approach to managing import programs, providing flexibility for essential pharmaceutical products while maintaining strict deadlines for other sectors. The measure aims to prevent disruptions in the supply chain for critical goods within الجزائر, ensuring that vital medical and pharmaceutical supplies continue to flow without impediment. This specific exemption shows the government's priority in maintaining access to essential medicines and health-related products.
Context of the Clarification
The Professional Association of Banks and Financial Institutions based its recent directive on import program deadlines on an official communication from the Ministry of Foreign Trade and Export Promotion. That communication, dated August 26, provided the foundational guidance for the association's instructions to bank executives regarding import files for the first half of 2026. The Ministry’s message outlined the parameters and timelines that subsequently informed the association's clarification on the validity of estimated import programs, ensuring a consistent and unified approach across all financial institutions. This establishes the regulatory origin of the deadlines and exceptions communicated to financial institutions, emphasizing the collaborative effort between governmental bodies and the banking sector. The August 26 communication from the Ministry of Foreign Trade and Export Promotion ensures a standardized approach across the banking sector for managing import operations, fostering transparency and predictability in trade procedures.
Program Validity and Next Steps
The Professional Association of Banks and Financial Institutions issued the directive concerning import program deadlines as correspondence number 606/2026. This specific numbering identifies the official communication to bank executives regarding the management and equipment programs for the first half of 2026, ensuring its traceability and official recognition within the banking system. The association further clarified that estimated import programs that require prior authorization from the Ministry of Pharmaceutical Industry will retain their validity until December 31, 2026. This extension for pharmaceutical imports provides a longer window compared to the general deadline for other items, acknowledging the specific regulatory requirements and lead times associated with these critical products. This extended validity period for pharmaceutical imports is a significant detail, providing ample time for the processing of these specialized import programs.
